Showing 1801-1810 of 3187 results for "".
EHR User Series: The Search for EHR Mobility
https://practicaldermatology.com/topics/practice-management/ehr-user-series-the-search-for-ehr-mobility/21225/In the electronic age, a truly mobile EHR may be key in the pursuit of fast, efficient medical care.The Price of a Penalty: Unraveling CMS's Latest Moves
https://practicaldermatology.com/topics/practice-management/the-price-of-a-penalty-unraveling-cmss-latest-moves/21435/State Legislation of EHRs: A Sweeping Precedent?
https://practicaldermatology.com/topics/practice-management/state-ehr-legislation-a-new-precedent/21483/A new law in Massachusetts requires all licensed physicians to be using an EHR by 2015.Analyzing the New Consensus Statement on Immunotherapy for Melanoma
https://practicaldermatology.com/topics/skin-cancer-photoprotection/analyzing-the-new-consensus-statement-on-immunotherapy-for-melanoma/21506/In-Review: Two New Melanoma Agents Approved
https://practicaldermatology.com/topics/skin-cancer-photoprotection/in-review-two-new-melanoma-agents-approved/21534/Utilizing genetic abnormalities, new therapies are carving out new possibilities for melanoma treatment.Financial Benchmarking Update for Dermatology Practices
https://practicaldermatology.com/topics/practice-management/financial-benchmarking-update-for-dermatology-practices/21621/Successful practices use benchmarking to compare their performance to others, assess their own performance over time, and plan for the long term.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/21848/Dermatology Q&A: Treating Melasma and Photoaging Without Hydroquinone
https://practicaldermatology.com/topics/general-topics/dermatology-qa-treating-melasma-and-photoaging-without-hydroquinone/21867/A recently unveiled skin brightening cream may signal a new direction in the treatment and prevention of pigmentation disorders.GLP-1 Receptor Agonists and the Aesthetic Patient: Considerations for the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1-receptor-agonists-and-the-aesthetic-patient/48900/The impact of glucagon-like peptide-1 agonists (GLP-1), such as semaglutide, tirzepatide and liraglutide, has transformed the healthcare industry and, in particular, aesthetic dermatology. The most common intended use of these medications, namely diabetes management and weight loss, can lead to a muCutaneous Manifestations Associated with Nemolizumab
https://practicaldermatology.com/issues/september-2025/cutaneous-manifestations-associated-with-nemolizumab/37628/In the 2025 study by Sasaki et al entitled “Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan,” nemolizumab-induced cutaneous eruptions were found to be relatively common, typically occu